| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 5 Aug 2025 | 21 Jul 2025 |
| Lupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2025 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter Ended June 30 2025. Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2025. (As Per BSE Announcement Dated on: 05.08.2025) | ||
| Board Meeting | 14 May 2025 | 29 Apr 2025 |
| Lupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2025 inter alia to consider and approve Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31 2025 and recommend dividend if any. Outcome of Board Meeting - Audited Financial Results for the quarter and year ended March 31, 2025 and recommendation of Dividend Recommended a Dividend of ? 12/- (Rupees Twelve only) per Equity Share (i.e. 600%) of the face value of ? 2/- (Rupees Two only) each fully paid up, for the financial year ended March 31, 2025, subject to approval of the Members at the ensuing Annual General Meeting (AGM). The Dividend shall be paid within 30 days from the date of approval by the Members at the ensuing AGM. (As Per BSE Announcement Dated on 14.05.2025) | ||
| Board Meeting | 31 Mar 2025 | 31 Mar 2025 |
| Outcome of the Board Meeting held on March 31, 2025. | ||
| Board Meeting | 11 Feb 2025 | 27 Jan 2025 |
| LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine-months ended December 31 2024 and other business matters. Outcome of Board Meeting - Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (As Per BSE Announcement Dated on 12.02.2025) | ||
| Board Meeting | 7 Nov 2024 | 22 Oct 2024 |
| Quarterly Results LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2024 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2024. Read less.. (As Per BSE Announcement Dated on 22.10.2024) Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2024. (As Per BSE Announcement Dated on: 07/11/2024) | ||
The launch aligns with Lupin’s strategic push into injectables, biosimilars, and inhalation therapies, supported by robust R&D and manufacturing capabilities
Here are some of the stocks that may see significant price movement today: Bharti Airtel, Torrent Power, Lupin Limited, etc.
This is eligible for 180 days of generic drug exclusivity. The company will manufacture the product at its facility situated in India.
Here are some of the stocks that may see significant price movement today: Godrej Properties, SBI Cards, Hyudai India, etc.
The tablets will be made at the company’s Goa facility, a site that has previously cleared global regulatory inspections and supports Lupin’s key exports.
The company said this deal fits into its larger strategy of expanding respiratory therapies beyond its home markets.
StainCares added that partnership plans to enhance its biosimilar portfolio and back cost-effective healthcare in Latin America.
Here are some of the stocks that may see significant price movement today: Lupin, IndiGo, Nazara Tech, Aurobindo Pharma, etc.
The drug will be manufactured at Lupin's facility in Nagpur, India, and the company has announced plans for a near-term launch in the U.S. market.
The clearance is on the back of a four-day USFDA inspection between June 10 and June 13, 2024.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
